Table 3 Characteristics of patients with different blood pressure control status

Demography

 Female (n, %)

72 (75.8%)

54 (71.1%)

12 (75.0%)

0.313

 Age (years, IQR)

31 (24–42)

34 (22–39)

29 (21–38)

0.411

Hypertensive severity (n, %)

 Moderate

34 (35.8%)

17 (22.4%)

5 (37.5%)

0.287

 Severe

44 (45.3%)

33 (46.1%)

10 (56.3%)

0.114

Echocardiography (n, %)

 Severe AR

9 (9.5%)*

6 (7.9%)^&

4 (25.0%)

< 0.001

Imaging phenotype (n, %)

 Cluster 1

17 (17.9%) ^#, *

25 (32.9%)

5 (31.3%)

0.035

 Cluster 2

26 (27.4%) ^#,*

7 (9.2%)

2 (12.5%)

< 0.001

 Cluster 3

52 (54.7%)

44 (57.9%)

9 (56.3%)

0.301

Immunosuppressive treatment

 Glucocorticoid (prednisone, mg/day, IQR)

35 (15–40)

30 (7–40)

30 (15–40)

0.317

 Cyclophosphamide (n, %)

20 (21.2%)

13 (17.1%)

5 (31.3%)

0.289

 Leflunomide (n, %)

21 (22.1%)

14 (18.4%)

4 (25.0%)

0.376

 Biological agents (n, %)

11 (11.6%)

4 (5.3%)

2 (12.5%)

0.053

Anti-hypertensive treatment

 Number of antihypertensive drugs (kinds, IQR)

2 (1–3)

3 (1–4)

3 (2–4)

0.074

 CCB (n, %)

69 (72.6%)

55 (72.4%)

12 (75.0%)

0.428

 ACEI/ARB (n, %)

32 (33.7%)*

18 (23.7%)

2 (12.5%)

0.029

 β-blocker (n, %)

61 (64.2%)*

39 (51.3%)

5 (31.3%)

0.033

 Diuretic (n, %)

23 (24.2%)

17 (22.4%)

6 (37.5%)

0.217

 Clonidine (n, %)

4 (4.2%)*

5 (6.6%)^&

4 (25.0%)

0.015

Revascularization operation (n, %)

28 (29.5%)

25 (32.9%)

5 (31.3%)

0.221

Events free survival by the end

71.8%*

65.8%

50.0%

0.041